welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy

key information

study id #: NCT01847573

condition: Duchenne Muscular Dystrophy

status: terminated


The main purpose of this study is to test the safety and tolerability of different, increasing doses of an experimental medication called HT-100 in boys and young men with Duchenne muscular dystrophy (DMD). The study medication, HT-100, is a medicine that may help promote healthy muscle regeneration, diminish inflammation and the resulting damage to muscle, and decrease the scar tissue that forms in the muscles of children with DMD. In this study, pharmacokinetic sampling, or measurements of the amount of HT-100 in the bloodstream will also be taken.

intervention: HT-100

mechanism of action: Small molecule designed to reduce fibrosis and inflammation

results: https://clinicaltrials.gov/ct2/show/results/NCT01847573

last updated: September 08, 2020